Vertaling van "diet in renal disease " (Frans → Nederlands) :

D’après la Modification of Diet in Renal Disease Study chez des patients insuffisants rénaux non diabétiques, il est recommandé chez les patients présentant une insuffisance rénale progressive et une protéinurie > 1 g/24 heures, d’atteindre une tension artérielle - mesurée de préférence le matin avant de prendre le médicament - inférieure ou égale à 125/75 mmHg.
Op basis van de Modification of Diet in Renal Disease Study, bij niet-diabetische patiënten met nierfalen, wordt bij patiënten met progressieve nierinsufficiëntie en met een proteïnurie van > 1 g/24 uur, een bloeddruk van 125/75 mmHg of minder aanbevolen, bij voorkeur gemeten ‘s morgens vóór de inname van de medicatie.

- Le débit de filtration glomérulaire, calculé par la formule MDRD (Modification of Diet in Renal Disease), est considéré comme un meilleur indicateur de la fonction rénale que la clairance de la créatinine estimée.
- De glomerulaire filtratiesnelheid, berekend met de MDRD (Modification of Diet in Renal Disease)-formule, wordt beschouwd als een betere indicator van de nierfunctie dan de creatinineklaring.

Annotation 2: Modification of Diet in Renal Disease (MDRD)(1999): DFGe (ml/min/1,73m²) = 186 x (créatinine sérique) -1,154 x âge -0,203 x (0,742 chez la femme) x (1,212 chez les personnes de couleur) (c’est une formule d’origine) 45 .
Noot 2: Modification of Diet in Renal Disease (MDRD) (1999): eGFR (ml/min/1,73m²) = 186 x (serumcreatinine) -1,154 x leeftijd -0,203 x (0,742 bij vrouwen) x (1,212 bij kleurlingen) (Dit is de oorspronkelijke formule 46 ).

Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease perioperative risks ii . NICE Minor surgery: ASA I : not indicated ASA II : consider > 40 y if respiratory or CV disease ASA III : consider if respiratory or CV disease Intermediate surgery: ASA I : not indicated ASA II : consider if respiratory or CV disease (renal > 60y) ASA III : consider if respiratory, CV or renal disease Major surgery: ASA I : consider > 60 ASA II : consider if respiratory, CV or renal disease ASA III : consider if respiratory, CV or renal disease
Source Statement ACA Not included ACP Not included ASA Selected patients : Agreement : 90 % of consultants, 92 % ASA Members To consider : smoking, recent infection, COPD, and cardiac disease ICSI Selected patients with signs or symptoms suggesting new or unstable cardiopulmonary disease INAHTA Chest X-ray abnormality correspond more closely with ASA status than with age (McCleane) i The results of between 0% and 2.1% of chest X-rays leads to a change in management There is no published evidence that routine preoperative chest X-rays decrease

Haemostasis No No No, consider if renal disease Renal function No Consider > 40y, Yes Yes if renal or CV disease
Statement Glucose Consider > 40y No No, consider if renal disease

R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editorial) Ann Intern Med 135 : 138-139(2001)
R.W. Schrier en R.O. Estacio: The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials (Editoriaal) Ann Intern Med 135 : 138-139(2001)

Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): Executive summary.
2011: Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused update of the guideline for the management of patients with peripheral artery disease.

L’étude ROADMAP (Randomized olmesartan and diabetes microalbuminuria prevention study) et l’étude ORIENT (Olmesartan reducing incidence of end stage renal disease in diabetic nephropathy trial) ont toutes deux révélé un nombre significativement plus élevé de décès d’origine cardiovasculaire dans le groupe actif versus placebo.
Zowel in de ROADMAP studie (Randomized olmesartan and diabetes microalbuminuria prevention study) als in de ORIENT studie (Olmesartan reducing incidence of end stage renal disease in diabetic nephropathy trial) waren er significant meer cardiovasculaire overlijdens bij de actief behandelde groep dan bij de placebogroep.

Glucose Consider No No, consider if renal disease > 40y
Blood gases No Consider if Consider respiratory disease

Full blood count Consider Consider Consider, yes if renal disease > 40y
Renal function No Consider > 40y, Yes if renal or CV disease